

James S Novak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7176270/publications.pdf>

Version: 2024-02-01

17
papers

626
citations

758635

12
h-index

794141

19
g-index

20
all docs

20
docs citations

20
times ranked

994
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of genetic background on the dystrophic phenotype in <i>mdx</i> mice. <i>Human Molecular Genetics</i> , 2016, 25, 130-145.	1.4	166
2	TGF- β -driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model. <i>JCI Insight</i> , 2020, 5, .	2.3	87
3	Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. <i>Molecular Therapy</i> , 2017, 25, 2561-2572.	3.7	63
4	TNF- α -Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. <i>Cell Reports</i> , 2015, 12, 1678-1690.	2.9	62
5	Germline Quality Control: eEF2K Stands Guard to Eliminate Defective Oocytes. <i>Developmental Cell</i> , 2014, 28, 561-572.	3.1	55
6	Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. <i>Nature Communications</i> , 2017, 8, 941.	5.8	44
7	Elusive sources of variability of dystrophin rescue by exon skipping. <i>Skeletal Muscle</i> , 2015, 5, 44.	1.9	26
8	Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis. <i>Journal of Pathology</i> , 2019, 249, 215-226.	2.1	24
9	Human muscle stem cells are refractory to aging. <i>Aging Cell</i> , 2021, 20, e13411.	3.0	18
10	Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in <i>mdx</i> mice. <i>Journal of Pathology</i> , 2019, 248, 339-351.	2.1	16
11	Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5575.	1.8	16
12	The macrophage as a Trojan horse for antisense oligonucleotide delivery. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 463-466.	1.5	13
13	Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, S383-S402.	1.1	13
14	Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 534-542.	2.3	7
15	Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy. <i>Life</i> , 2021, 11, 827.	1.1	6
16	Anoctamin 5 Knockout Mouse Model Recapitulates LGMD2L Muscle Pathology and Offers Insight Into in vivo Functional Deficits. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, S243-S255.	1.1	5
17	Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, S369-S381.	1.1	1